Alnylam Additional Positive Interim Phase 1 Data for Alzheimer’s, Cerebral Amyloid Angiopathy

 Single Doses of ALN-APP Achieve Sustained Pharmacodynamic Activity up to 10 Months After Administration –

– Observed Marked Reductions in Aβ₄₂ and Aβ₄₀, Amyloid Fragments Implicated in Alzheimer’s Disease and Cerebral Amyloid Angiopathy –

– First Patient Dosed in Multiple-dose Part B Portion of Study, with the Study Proceeding in Canada, UK, and the Netherlands –

https://www.biospace.com/article/releases/alnylam-reports-additional-positive-interim-phase-1-results-for-aln-app-in-development-for-alzheimer-s-disease-and-cerebral-amyloid-angiopathy/